Jazz Pharmaceuticals PLC

2026. g. 6. okt. 20:07 UTC

Jazz Pharmaceuticals PLC shares declined after Director Bruce C. Cozadd sold 6k shares, with the stock remaining significantly below its 20-day moving average.

2026. g. 1. okt. 19:25 UTC

Jazz Pharmaceuticals PLC is trading higher, reflecting positive movement since Wednesday's close, despite retracing from an earlier peak and remaining below its 20-day moving average.

2026. g. 30. sept. 20:07 UTC

Jazz Pharmaceuticals PLC shares fell as the broader market showed weakness, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

2026. g. 29. sept. 20:02 UTC

Jazz Pharmaceuticals PLC shares fell sharply, reaching their lowest cumulative return since Monday and trading well below the 20-day moving average.

2026. g. 28. sept. 20:51 UTC

Jazz Pharmaceuticals PLC rose significantly in after-market trading, advancing notably since Monday's close, despite earlier fluctuations into negative territory.

2026. g. 25. sept. 19:15 UTC

Jazz Pharmaceuticals PLC is trading modestly higher, having peaked at nearly 1% earlier, though it remains below its 20-day moving average.

2026. g. 24. sept. 21:03 UTC

Jazz Pharmaceuticals PLC is trading modestly lower in after-market hours, struggling to maintain gains and dipping below its 20-day moving average.

2026. g. 23. sept. 20:02 UTC

Jazz Pharmaceuticals PLC shares fell sharply, reaching an early high before declining significantly, currently below the 20-day moving average and near a one-month low.

2026. g. 22. sept. 19:16 UTC

Jazz Pharmaceuticals PLC shares fell modestly, currently trading below their 20-day moving average and near the lower end of their one-month range.

2026. g. 21. sept. 20:51 UTC

Jazz Pharmaceuticals PLC's stock has declined in after-market trading, remaining significantly below its 20-day moving average and near the bottom of its one-month trading range.

2026. g. 18. sept. 20:06 UTC

Jazz Pharmaceuticals PLC shares fell sharply, reaching a session low amid broader market performance challenges and remaining below its 20-day moving average.

2026. g. 17. sept. 20:13 UTC

Jazz Pharmaceuticals PLC saw a modest decline during after-market hours on Thursday, remaining below its 20-day moving average amid broader market weakness.

2026. g. 15. sept. 20:02 UTC

Jazz Pharmaceuticals PLC's acquisition of Actio Biosciences for $820 million enhances its epilepsy pipeline, but shares are lower today following an earlier peak.

2026. g. 11. sept. 20:02 UTC

UBS raised its price target on Jazz Pharmaceuticals to $337, maintaining a Buy rating amid confidence in growth prospects. Shares are trading higher today.

2026. g. 8. sept. 20:03 UTC

Jazz Pharmaceuticals PLC is declining amid broader pharmaceuticals sector weakness, breaking a recent trend of higher daily closes since Friday.

2026. g. 4. sept. 19:36 UTC

Jazz Pharmaceuticals PLC shares are lower today amid rising Treasury yields and strong labor market data, reflecting broader market trends.

2026. g. 3. sept. 21:21 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, reflecting ongoing pressure despite broader market strength and decreasing rate hike expectations.

2026. g. 2. sept. 19:46 UTC

Jazz Pharmaceuticals PLC shares are higher today, despite an earlier pullback. Broader market conditions include rising U.S. Treasury yields amid inflation concerns.

2026. g. 1. sept. 19:54 UTC

Jazz Pharmaceuticals shares are lower despite positive Phase 3 trial results for Ziihera, influenced by tightening monetary policy expectations and rising Treasury yields.

2026. g. 31. aug. 23:41 UTC

Jazz Pharmaceuticals PLC reported positive results from the HERIZON-GEA-01 trial for Ziihera, leading shares higher in after-hours trading.

2026. g. 28. aug. 20:02 UTC

Jazz Pharmaceuticals PLC shares are lower today, reversing a trend of higher closes. Broader market pressures include rising U.S. Treasury yields amid inflation concerns.

2026. g. 26. aug. 20:08 UTC

Jazz Pharmaceuticals PLC shares are lower following a $1 billion note offering and potential $225 million buyback, despite positive FDA approvals and target raises from analysts.

2026. g. 25. aug. 20:07 UTC

Jazz Pharmaceuticals rises on FDA approval of Ziihera for treating advanced HER2-positive gastroesophageal cancer. Bank of America sets price target at $307.

2026. g. 24. aug. 19:26 UTC

Jazz Pharmaceuticals shares are lower amid broader market sentiment influenced by geopolitical tensions. Ziihera's potential in the HER2+ market presents a growth opportunity.

2026. g. 22. aug. 00:02 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline since Friday's close, despite broader gains in major U.S. stocks.

2026. g. 21. aug. 20:06 UTC

Jazz Pharmaceuticals PLC shares are higher during Friday's session, reflecting strong upward momentum since Thursday's close, despite a recent pullback from session highs.

2026. g. 20. aug. 19:56 UTC

Jazz Pharmaceuticals PLC shares are lower amid a broader market decline following disappointing sales growth and guidance from Walmart. They remain below their 20-day moving average.

2026. g. 19. aug. 22:36 UTC

Jazz Pharmaceuticals PLC shares are lower in after-market hours, continuing a decline from regular trading, despite a broader recovery in equities.

2026. g. 18. aug. 20:03 UTC

Jazz Pharmaceuticals shares are trading higher, reflecting strength in the pharmaceuticals sector, despite a slight pullback from earlier session gains.

2026. g. 17. aug. 23:31 UTC

Jazz Pharmaceuticals PLC shares declined during after-market hours, reflecting broader market pressures from rising crude oil prices amid escalating U.S.-Iran tensions.